<DOC>
	<DOCNO>NCT01792986</DOCNO>
	<brief_summary>This study determine whether intensive fast protocol alters hemoglobin A1c measurement marker metabolic cardiovascular risk perform 5-week clinical trial fasting among 12 pre-diabetic individual diabetic whose disease control diet . Participants undergo 5-week intervention once-per-week 24-hour water-only fasting , include baseline end week week study ( total 6 24-hour fast ) .</brief_summary>
	<brief_title>The Fasting II Study</brief_title>
	<detailed_description />
	<mesh_term>Metabolic Diseases</mesh_term>
	<criteria>1 . Male nonpregnant female , ≥30 &lt; 70 year age . 2 . Ability understand sign write informed consent form , must obtain prior initiation study procedure . 3 . Prior evidence prediabetic state , one following : 1 . Prediabetic measure hemoglobin A1c ( HbA1c ) ≥6.0 % fast glucose &gt; 100 mg/dL without clinical diabetes diagnosis 2 . Clinicallydiagnosed type II diabetic HbA1c ≥6.0 % fast glucose ≥110 mg/dL whose disease control diet alone . 4 . Evidence metabolic syndrome least 3 follow 5 criterion : 1 . Fasting glucose level &gt; 100 mg/dL . 2 . Blood pressure ≥135 mmHg systolic ≥85 mmHg diastolic , use antihypertensive medication . 3 . Highdensity lipoprotein cholesterol &lt; 40 mg/dL male &lt; 50 mg/dL female . 4 . Triglycerides ≥150 mg/dL use cholesterollowering medication . 5 . Waist circumference &gt; 40 inch ( 102 cm ) males &gt; 35 inch ( 88 cm ) female ( body mass index &gt; 25 kg/m2 ) . 1 . Pregnant and/or lactate woman woman child bear potential use acceptable mean contraception . Women childbearing potential must use adequate measure contraception ( determine Principal Investigator ) avoid pregnancy highly unlikely conceive study period . Women childbearing potential must negative pregnancy test screen . 2 . Diabetics take follow antidiabetic medication : insulin , metformin , thiazolidinediones , sulfonylurea , alphaglucosidase inhibitor , meglitinides , incretins . 3 . Prior experience fast per month ( 20 hour ) , average last year . 4 . Very low body mass index ( BMI ) ( &lt; 18.5 kg/m2 ) high BMI ( &gt; 40 kg/m2 ) . 5 . Individuals nutritionally compromise , assess Principal Investigator . 6 . Any immunodeficiency prior solid organ transplantation renal disease . 7 . Participation clinical trial involve investigational market product within 30 day prior entry study . 8 . Other condition opinion Principal Investigator may increase risk subject and/or compromise quality clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Fasting</keyword>
	<keyword>Pre-diabetes</keyword>
	<keyword>Hemoglobin A1C</keyword>
</DOC>